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ABSTRACT 
In 2007, a gene homolog of CDO encoded by the gene Gm237 in the DUF164 family 
was identified as cysteamine dioxygenase (ADO).  ADO is one of the only known thiol 
dioxygenases found in mammals.  Both ADO and its partner cysteine dioxygenase (CDO) are 
non-heme iron dependent enzymes that play a crucial role in the biosynthesis of 
taruine/hypotaurine by insertion of a dioxygen molecule.  However, ADO has been 
overshadowed by CDO as heavy research focus on CDO over the past decade has led to the 
elucidation of its structure and possible mechanistic properties. In an effort to further understand 
ADO’s mechanism and regulating role in vivo, this work will be focused on the mammalian 
hADO and trying to gain further insight on hADO’s structural features via crystallography work.  
Investigation of the crystallization parameters for hADO has elucidated several potential 
conditions. Detailed work on these crystallization parameters will be presented. 
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1 INTRODUCTION  
Enzymes are proteins which functions as biological catalysts.  Enzymes are produced in all 
living organisms and are necessary in almost all metabolic processes to sustain life1Enzyme 
properties are versatile and to date enzymes are used in various assets of applications ranging 
from the food and beverage industry, starch and fuel production, organic synthesis, 
pharmaceutical etc.  Due to evolution of modern biotechnology and protein engineering the 
possibilities of utilizing enzymes in multiple facets of life have become possible.2 However, all 
of these possibilities would not be available if not for the understanding of enzymes at the 
molecular and biological levels.    
Enzymes are composed of the building blocks called amino acids.  There are 20 key amino 
acids utilized by the body’s proteins and they are either obtained from food or synthesized by the 
body.  When amino acids form polypeptides, they can fold to form three-dimensional structures 
due to hydrophobic forces and intermolecular interactions between the amino acid residues.  The 
structure formed is significant to the amino acid sequence allowing the enzyme to have different 
folds and reactive chemical nature.  Enzymes can bind specific substrates via different enzyme 
binding affinities such as the lock and key model.  Many enzymes tend to require cofactors such 
as metals, flavin, NAD, etc to perform these enzymatic activities. One key class of enzyme that 
incorporates metals is called metalloenzymes.  Metalloenzymes are all protein associated with a 
metal ion to form a coordinative active site for catalytic activity.  Some mettalloenzyme classes 
fall under heme and non-heme enzymes where heme enzymes are associated with presence of an 
iron porphryin which bonds via covalently or non-covalently interactions and non-heme enzymes 
which lack presence of a heme.   
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Enzymes have been studied since the 1800s and remain to be the focal point of many 
research investigations to date.  The biological identification of enzymes remained elusive until 
the early 1900s when James B. Sumner showed that the enzyme urease was in a fact a protein 
and crystallized it..3 Sumner’s crystallization work opened up the doors for new investigative 
premises of enzymes as the discovery that proteins can be crystallized allowed for the structure 
analysis of enzymes by x-ray crystallography.  Structural biology or protein crystallography has 
allowed for the study of enzymes at the atomic level and remains to be a key tool for 
understanding the structure and function of an enzyme.   
 
1.1 Protein Crystallography  
The discovery of X-rays in the late 1800s along with subsequent developments by 
William Brag and his son revealed that X-ray diffraction could be used to determine the atomic 
structure of atoms.4 Their work proved to be the foundation for X-ray crystallography as years 
later, the first protein structure of myoglobin was determined and published.  Since then, 
macromolecule crystallography has become a practical tool utilized in various fields and 
applications because studies at the atomic level of molecules have proved to be of great value in 
revealing structure/function relationship; which is important for understanding how enzymes, 
nucleic acids, or other macromolecules will interact in a biological system. Crystallography 
studies have become of considerable interest to many different fields including academia, 
pharmaceutical, biotechnological, chemical industries, etc as a promising tool in protein 
engineering, drug design, and various other biological system studies such as understanding 
certain diseases.  The elaborate information obtained from the 3-dimensonal structure of a 
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protein or other biological macromolecule provides potential information on understanding 
mechanisms by which enzymes, receptor, hormones, lipids, etc. function in a biological setting. 5  
One key application of protein crystallography is utilizing the information obtained from 
the crystal structure to understand enzyme function and mechanism.  This involves 
understanding the chemical reaction taking place between the substrates, cofactors, etc. involved 
for the formation of a product and enzyme kinetics.  Understanding these aspects along with the 
cellular location of the protein allows insight on cellular regulation which can prove to be useful 
information for understanding the nature of particular diseases or abnormal malfunctions.  
Information from the structure of proteins can also identify mutational consequences which can 
affect enzyme function.  There are various types of mutations: substitution, deletion, inversion, 
etc. causing the enzyme to be improperly folded or lose/gain enzyme function.  Thus, mutations 
can greatly affect enzyme activity and cause imbalance in cellular regulation leading to diseases.  
Structural crystallography relies mainly on the scattering of X-rays by the electrons in the 
molecules of the investigated sample.  The crystal is exposed to an X-ray beam and exposed at 
various orientations resulting in the scattering of X-ray radiation in selected directions.  
Scattering is governed by the geometry of the crystal unit cell while the intensity of the 
diffractions depends on the grouping of all atoms within the unit cell. This property allows for 3-
D diffraction gratings unique to the geometry of the protein.  Thus, in general the crystal 
structure is encoded in the diffracted X-rays and its intensities which is defined by the shape and 
symmetry of the cell.  The position of each atom in the unit cell influences the intensities of the 
reflections.  The primary result from the X-ray diffractions is a map of the electron density 
within the crystal and after proper refinement the electron density map can be then be processed.  
Several programs today such as Mosflm, XDS, and HKL-2000 were developed for processing 
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electron density maps.  From the electron density map, a structural model can be built, often with 
the assistance of the amino acid sequence information (i.e., the primary structure). The clarity of 
the electron maps depends on the resolution of the diffraction data.  At low resolutions, it is not 
possible to accurately locate or distinguish between individual atoms and their identity.  
However, with increasing resolution, it becomes possible to identify the stereochemistry of 
individual amino acids and peptide groups to give a clear layout of the protein structure. 
Macromolecule crystallography has come a long way as today there is establishment of a Protein 
Data Base (PDB) as a repository site for all solved crystal structures.  As of today, there are at 
least 37,914 deposited crystal structures. 
 
1.2 Protein Dynamic Growth  
Protein crystallization is a complex process with various parameters that must be taken 
into consideration. One key parameter is the nature and the properties of the protein being 
crystallized.  Proteins tend to be large, complex molecules which can compose of several 
subunits.  This can cause proteins to have varying molecular and dynamic properties depending 
on the protein’s amino acid sequence which can affect protein crystallization.  This can include 
but is not limited to relatively flexible structures, chemically or physically instable 
conformations, unique three-dimensional folds, or charge and size of the protein.  For a crystal to 
form, it does not depend on the properties of the protein alone.  The interactions between protein 
molecules and its surrounding solution environment must align properly to from a crystal with 
specific geometric arrangement.  Surrounding environmental factors such as pH, ionic strength, 
temperature, concentration of protein, etc as shown in Figure 1 are all factors that must be taken 
into consideration.  Even today, it is still not possible to predict the crystallization conditions of a 
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protein as change in a single experimental parameter can influence the outcome of a 
crystallization experiment.   
Crystallization is an intricate process that involves multiple equilibria between different 
states of the species being crystallized.  There are three stages commonly associated with 
crystallization: 1. nucleation  2. crystal growth 3. cessation of growth.  Nucleation occurs when 
enough molecules associate in three dimensional forms, resulting in a thermodynamically stable 
aggregate which provides a suitable platform for crystal growth.  Crystal growth and nucleation 
occur in supersaturated solutions when the concentrations of the crystallized species exceed 
equilibrium solubility.  However, the ideal conditions for suitable crystallization conditions are 
finite due to many different factors. 6 Therefore, it is important to guide the process toward a 
state of reduced solubility by modifying various parameters to ensure that solubility is decreased 
at a slow rate with respect to the nature of the species being crystallized in order to ensure that 
orderly crystals are formed instead of amorphous precipitate. The ideal approach would be to 
begin at the lowest supersaturation and slowly increase saturation due to depletion of solute from 
the solution as this allows the nuclei to grow properly and allow formation of define and stable 
crystals which will diffract. 7 
A wide variety of chemical, physical, and biochemical parameters affect the protein 
crystallization process.  The purity of the protein being analyzed, the properties of the solution 
being used for crystallization (e.g. salts, buffers, pH, temperature), and the various techniques 
used for sampling handling are all important factors that must be taken into consideration.  Table 
1.2 lists some common parameters that are taken into consideration for protein crystallization.  
Table 1. Environmental factors for protein crystallography. Adapted from ref 8&10. 
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Physical Factors  Chemical 
Factors 
  Biochemical 
Factors 
Temperature  Precipitant type   Sample purity 
Time  Precipitant 
concentration 
  Macromolecular 
impurities 
Pressure  pH and buffer   Aggregation 
Methodology  Ionic strength   Posttranslational 
Modifications 
Gravity/Sedimentation  Reducing/oxidizing 
environment 
  Sample source 
Vibrations/Sounds  Sample 
concentration 
  Chemical 
modifications 
Magnetic/Electric  Fields  Metal ions   Sequence 
modifications 
Viscosity  Detergents   Sample 
symmetry 
Equilibration rate  Polyions   Ligands, co-
factors, 
inhibitors 
Volume  Cross-linkers   Sample pI 
Surface of crystallization  Reagent source   Purification 
methods 
Sample handling     Microbial 
contamination 
      
 
 
With so many parameters to be considered, there is no exact approach to determine the 
proper conditions that must be used to crystallize a protein.  A few parameters will be briefly 
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discussed here, however more explicit reviews on the different parameters are explained in 
sources. 8,10 
1.2.1 Ligand/Substrate/Cofactors Parameter 
It is often possible to increase the stability of a protein via addition of a  ligand, substrate, 
nucleic acid, cofactor, or small molecule. 11 The ligand or stabilizing molecule can be added 
during various stages to the protein whether if it’s during certain protein purification steps, 
during the entire purification process, or during the final concentration before crystallization.  
The addition of a ligand may help to stabilize the protein and lessened or elimination issues such 
as protein denaturation.  It is also applicable to soak the ligands into pre-existing crystals to form 
and trap key intermediates to help elucidate the enzymatic pathway.  It has been shown that 
certain proteins when expressed with a ligand of interest can help protein expression and increase 
protein solubility. 12,13 Addition of ligand during the various purification steps of protein 
purification such as cell-lysis was the key for the success of obtaining pure protein as seen for 
the crystallization of a recombinant enzyme (kinase 1) from a baculovirus in insect cells.  
If no ligand was present, purification of the enzyme resulted in a mixture of protein, 
DNA, and lipids.  If the ligand is soluble, the protein-ligand complex can be formed by adding 
the ligand to the protein during the final steps of concentration. It has also been noted that 
cofactors such as metals can be a key parameter for crystallization conditions. Many enzymes 
requires metals such as Fe, Mg, Ni, etc to be biologically active.  For this reason, it is reasonably 
expected that incorporating metals, particularly divalent metals to metal dependent enzymes 
would help with crystal formation.  This could be due to the fact that metal ions can stabilize the 
protein and the intermolecular interactions in the crystals.14,15 
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1.2.2 Precipitants 
Protein solubility can be varied by changing the composition of the solution.  This can be 
by changing solubility-influencing additives such as alcohols, detergents, hydrophilic polymers, 
etc. which are commonly referred to as precipitants.  Listed in table 2 are common precipitants.  
There are four broad categories for protein precipitants: salts, organic solvents, polymers, and 
non-volative organic compounds.   
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Table 2. Lists of additives that can affect protein solubility. Adapted from ref 8 & 10. 
 
Salts                 Organic Solvent    Polymers 
Ammonium or sodiumn  sulfate Ethanol    Poly(ethylene) 
glycol 1000, 
3350, 6000, 
20000, etc. 
Lithium sulfate Isopropanol    Jeffamine T 
Lithium chloride 1,3- propandediol    Polyamine 
Sodium/ammonium/potassium chloride Acetone     
        Sodium/ammonium acetate Butanol     
       Magnesium/calcium sulfate Acetonitrile     
      Cetyltrimethyl ammonium salts Dimethyl sulfoxide     
Calcium chloride 2,5-hexanediol     
Sodium formate Methanol     
Ammonium nitrate 1,3-butyrolactone     
       
 
The ionic strength of the solution can be increased to decrease the solubility of a protein 
by a method referred to as “salting out”.  As salt concentration increases, water molecules are 
monopolized and form bonds with the small salt ions, causing the protein to aggregate.  This 
interaction could result in the ordered arrangement of proteins to form crystals.16  
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Addition of organic solvents also produces similar effects by competing for water.  This 
is due to the hydrogen bonding capabilities of organic compounds and leads to the aggregation 
and increase elastic forces between protein molecules.  The mechanisms of polymers to facilitate 
protein crystallization are still not yet clearly understand, however it has been observed that 
polymers also induce protein crystallization by competing with proteins for water and by 
lowering the dielectric constant of the solution.   
 
1.2.3 Other Parameters 
Various other parameters are important in crystallizing a protein by gradually forcing the 
protein to become less soluble.  Protein solubility is sensitive and typically relies greatly on 
parameters such as pH and temperature. 17 Most protein have been successfully been crystallized 
at their respective physiological pH.  It was once believed that proteins would be more readily 
crystallized at their respective pI, however further research has proven that at physiological pH, 
there is less risk of denaturation.  Temperature dependence of protein solubility is due to the 
protonation and deprotonation reaction constants of amino acid side chains.18 Protein 
concentration is also a key parameter to allow for proper crystal nucleation.  Common 
concentration ranges from 5 to 30 mg/mL but can range to even lower and higher concentrations 
depending on the solubility of the protein.  Protein crystals will form and can form at various 
concentrations but it has been identified that only at optimal concentrations will proteins 
crystallize with reproducibility and consistency.  The previously described parameters are only a 
few of many parameters that can influence protein crystallization. However, as of today there are 
still no clear definitive set of established parameters that can be associated as the key to 
successful protein crystallization as crystallization parameters will differ from protein to protein. 
11 
 
1.3 Cupin Family 
The Cupin superfamily is a diverse family of proteins with a conserved 6 β-barrel domain 
with a high diversity and range of biological functions as this family is associated with Archaea, 
Eubacteria, and Eukarota.19 The identity of the Cupin family originated from identification and 
recognition of a conserved motif found within proteins such as the wheat protein germin and 
germin-like proteins (GLPS).  Most proteins in this family shows low overall sequence 
similarities however, they each contain two distinct short conserved cupin sequence motifs 
Gx5HxHx3-6Ex6G (motif 1) and Gx5-7PxGx2Hx3N (motif 2), separated by a less conserved 
intermotif region (15-50 residues).  The patented “jelly roll” barrel is formed with the cupin 
motif 1 and 2 along with the intermotif region where each forms two of the core six β-strands 
found in the folded structure.  These degree of high hydrophobic interactions and short loops 
contribute to the thermal stability and protease resistant properties of proteins in this family.20   
The  Cupin superfamily consist of proteins with a wide range of biological functions 
including enzymatic activities such as decarboxylases, dioxygenases, hydrolases, isomerases, 
epimerases, and non-enzymatic functions such as seed storage or transcription factors.21  Studies 
have shown that activity and function of cupins probably originated with ancestral cupins as 
simple sugar and cyclic nucleotide non-enzymatic binding domains which eventually evolved to 
metal-coordinating enzymatic domains. 22 This was based on the fact that a set of conserved 
histidine residues can be traced back to the ancestral cupins.  A majority of the metal-dependent 
enzymes have been associated with metals such iron, nickel, zince, manganese, cobalt, or copper 
as each cofactor allows for a unique chemistry.  Well known enzymes in the cupin family such 
oxalate oxidase and oxalate decarboxylase have been determined to be able to coordinate with a 
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Mn ion.  Other enzymes in this family like acireductone dioxygenase binds Ni and praline-3-
hyroxylase utilizes Fe as a cofactor. Purposed mechanisms of these enzymes generally involve 
the sequential binding of the substrate and a dioxygen molecule to the metal cation. Initially 
metal binding enzymes in this family were thought to possess ligands consisting of 3 His-1-
carboxylate.  It is now however apparent that there are many variations in the sequence as 
deletions or substitutions of the ligands can result in alternate binding sites.  As of today, there 
are many notable variations of these ligands in the binding site due to structural characterization 
work.  For instance, the ligands of various enzymes can consist of 2-His, 2-His-1-Gln, 3-His, 3-
His-1-Glu, etc. 23 Efforts toward elucidating the structure and role of these metal binding 
enzymes has been beneficial for understanding the nature of metal binding enzymes and their 
mechanistic properties in vivo.  
 
1.3.1 Thiol Dioxygenase 
Our interest in the Cupin family revolves around a sub group of enzymes in this family 
called thiol dioxygenase.  In the mammalian cell there are many processes that can result in the 
oxidation of thiol groups due to the reactive free sulfhydryl groups to form disulfides, sulfinates, 
sulfenates, and sulfonates. Many of these oxidations occur nonenzymatically yet, there are still a 
number of thiol reactions that occur by enzymatic reactions. 24 It has been shown that there are 
enzymes involved in these reactions which can oxidize free sulfhydryl groups with high degree 
and specificity.  One interesting group of enzymes that can oxidize free sulfhydryl groups 
includes thiol dioxygenases cysteine dioxygenase (CDO) and cysteamine dioxgyenase (ADO).  
To date, CDO and ADO are the only two reported mammalian thiol dioxygenases. CDO and 
ADO are unique iron-dependent enzymes that adds molecular oxygen to sulfhydryl group to 
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form a sulfinic acid in cysteine metabolism. These two thiol dioxygenases are essential for 
hypotaurine/taurine biosynthesis.25  Cysteine and dioxygen are used as substrates by CDO to 
form cysteinesulfinic acid which can then (1) decarboxylate to hypotaurine or (2) transaminate to 
3-sulfinylpyruvate which can decomposes to pyruvate.  ADO on the other hand uses the 
substrate cysteamine, a decarboxylated cysteine derived during the coenzyme A synthesis 
pathway.  Once cysteamine is released during coenzyme A degradation, ADO converts 
cysteamine and dioxygen to form hypotaurine which is further oxidized to taurine (Figure 1).  
Thus, both CDO and ADO play key roles in thiol metabolism by regulating cysteine and 
cysteamine levels in the body for the production of hypotaurine/taurine from two different 
cysteine metabolites.  Thiol metabolism for the production of hypotaurine/taurine has become of 
importance because of the physiological relevance of taurine for cardiovascular function, the 
retina, and the central nervous system.26  
14 
 
Figure 1.  Taurine biosynthesis pathway from cysteine. Image adapted from ref. 27. 
 
1.3.1.1 CDO 
Yamaguchi and coworkers were able to successfully purify and characterize CDO from rat 
liver in the 1970s.  They discovered that CDO had the capability to bind one atom of iron per 
molecule and also went on to solve the amino acid sequence.28,29 Future contributions from other 
groups went on to discover that the 200 amino acid residue protein was identical for rat and 
murine CDOs while human CDO only differed by 16 amino acid residues.30 Influx of interest in 
CDO started when clinical evidence indicated that malfunction in cysteine metabolism  due to 
CDO can lead to altered cysteine to sulfate ratio which causes sulfate depletion along with other 
adverse effects.31,32 Other reports have shown that impaired cysteine catabolism was present in 
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patients afflicted with rheumatoid arthritis, liver diseases, Parkinson disease, Alzheimer disease, 
and systemic lupus erythematosus.  Depletion of cysteine catabolism would either cause a 
depletion of sulfate and taurine while leading to an accumulation of substrate cysteine which has 
been speculated to impair sulfation reactions in vivo.33,34,35 
SH
NH3
+
O
O
-
O2
S NH3
+
O
-
O
O
O
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Figure 2. Reaction catalyzed by CDO 
 
The elucidation of the crystal structure of CDO from rat, mouse, and human has revealed 
that it is indeed a member of the cupin family for it contained the patented cupin fold.  CDO 
contains a β-sandwhich of seven anti-parallel β-strands on the lower side (β1, β2, β4, β7, β9, 
β12, and β13) and six anti-parallel β-strands (β3, β5, β6, β8, β10, β11) on the upper region.31,36,37 
The cupin core is present in CDO as β-strands 3 and 4 corresponds to βC and βD (cupin motif 1), 
β-strands 5 and 6 corresponds to βE and βF (intermotif region), and β-strands 7 and 8 
corresponds to βG and βH (cupin motif 2). This illustration can be seen on Figure 3. 
Another interesting discovery is that CDO contained a novel metal center with Fe as its 
cofactor.  Instead of a 3-His-1-Glu variation, it was revealed that CDO coordinated Fe2+ by a 
facial triad of 3 histidine side chains without any carboxylate ligand present near the iron center.  
It was evident that no other residue replaced the conserved glutamate as a metal-coordinating 
ligand, thus indicating that CDO is a unique discovery as most monnuclear non-heme Fe2+ 
enzymes normally use the 2-His-1-Glu or 3-His-1-Glu coordination.  Therefore, the tetrahedral 
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coordination of mononuclear iron of CDO is unique for most cupin superfamily typically utilizes 
a penta- or hexa- coordination metal center.   Further work on CDO indicated that the novel 
center of CDO would catalyze reactions differently than other classes of dioxygenases.  Rather 
than cleavage of a C-C bond or hydroxylation, CDO involves oxidation of a sulfyhydryl group.  
Crystal structure of human CDO in complex with substrate L-cysteine36 along with crystal 
structure of rate CDO with Fe2+ bound persulfenate intermediate suggest that Fe2+ directly 
activates both cysteine and O2, causing a transfer of both oxygen atoms from the iron atom to a 
single sulfur atom.31 This is possible because of the electron rich substrate compound.  However, 
studying of the mechanism of CDO has proved to be quite challenging because both the substrate 
and resulting products are not detectable by UV-Vis absorption.   
Crystal evidence from mammalian CDO also indicated that there is a unique crosslink in the 
active site of the enzyme (Figure 3).  A Cys-Tyr intramolecular crosslink between Cys93 and 
Tyr157 is indicative of a rare thioether cofactor that has been identified to possibly play a role in 
regulating CDO function via a substrate-regulation from cysteine to modulate the Cys-Tyr 
cofactor formation as form of feed-forward activation.   
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Figure 3.  1.5 Å Resolution Crystal Structure of Recombinant R. Norvegicus Cysteine 
Dioxygenase illustrating the purin domain and a Cys-Tyr crosslink.  Image taken from ref. 31. 
(PDB 2B5H) 
 
1.3.1.2 ADO 
In 2007,studies were done on a hypothetical murine protein homolog of CDO encoded by 
the gene Gm237 in the DUF1647 family which was identified to show significant cysteamine 
dioxygenase activity in vitro.24 Sequence alignment of this murine protein homolog which was 
named ADO when compared to CDO only resulted in 14%-19% similarity.  However the 
alignment indicated that ADO belongs to the cupin family while also potentially exhibiting the 
same 3-His metal binding motif as CDO.  Upon its first discovery from horse kidney in 1963, 
ADO has been reported to require sulfide, elemental sulfur, selenium, or hydroxylamine to 
function.38 The recombinant ADO however, reported that the use of ferrous iron as a cofactor 
was necessary while requiring none of the exogenous elements mentioned previously.  To date, 
little information about ADO is known.  For several decades, a vast majority of the research 
effort was focused more on CDO because of CDO and its association as a major regulator of 
taurine synthesis.  However, association of cysteamine as a potential intermediate in taurine 
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biosynthesis for the cause of Hallervorden-Spatz syndrome has renewed interest. Lack of 
panthothenate kinase (PANK2) which is necessary for the synthesis of coenzyme A and release 
of cysteamine during coenzyme A degradation has been identified to be a cause of Hallervorden-
Spatz syndrome. 39 Furthermore, evidence also indicates that cysteamine could serve as an 
endogenous regulator of the immune system activity 40,41 and a potential therapeutic agent of 
Huntington disease. 42,43  
ADO like many other cupins possess the two conserved cupin motifs, however like CDO, 
it is missing the highly conserved glutamate in motif 1 as this residue is replaced by valine or 
glycine (compared to cysteine or glycine in CDO).  Motif 2 for the cupin family is less conserved 
among the DUF1637 family but all contain the third metal-binding histidine residue (His 193 in 
human ADO).  The alignment would suggest that this third histidine residue would be involved 
in iron ligand binding, however no direct evidence have suggested that.  Even though both CDO 
and ADO utilizes a thiol substrate to catalyze a similar reaction, it has been reported that ADO 
could potentially contain an iron binding site that is different from CDO due to ADO’s ability to 
retain bound iron while iron can dissociate rather easily from CDO.24,31  
For these reasons, it is necessary to pursue higher levels of understanding of ADO.  ADO 
is non-heme mononuclear iron dependent enzyme that catalyzes the oxidation of cysteamine to 
hypotaruine in the presence of oxygen.  Sequence alignment of various ADO strands indicates 
that ADO consist of multiple intriguing conserved and missing residues as shown by Figure 5.  
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Figure 4. Sequence alignment of various strands of ADO. 
Compasrison of hADO (1) with various strands of ADO.  Thee conserved glutamate is replaced by ether glycine or 
valine for ADO.  A potential cys-tyr crosslink similar to CDO can be also be seen.  Note: black highlights are from conserved 
residues similar to the cupin family and lighter highlights are for conserved residues within ADOs.27 
 
 
 
To date, no structure of ADO has been reported. The structure of an enzyme is a crucial factor 
for indebt mechanistic study and understanding the regulation roles of the enzyme in vivo.  For 
these reasons, we are highly interested in trying to pursue the structure of ADO. 
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Figure 5. Reaction catalyzed by ADO 
 
2     MATERIALS/METHODS 
2.1 hADO Purification 
The gene human ADO (hADO) was purchased from DNASU and was cloned to pET28 
plasmid with a His-tag and transferred into B L21 (DE3) competent cells.  The E-coli cells with 
hADO were grown in Luria Broth at 37oC with shaking at 200 rpm at first in 10 mL and then 
transferred to 50 mL medium size containing 10 mg/mL and 50 mg/mL kanamycin respective to 
the increasing Luria Broth size.  hADO cells from the medium scale was then transferred to a 
500 mL size Luria Broth with 100 mg/mL kanamycin.  The large scale culture was grown at 
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37oC with shaking at 200 rpm until O.D. was approximately 0.6.   At this point, the temperature 
was decreased to 25oC and induced with 0.6mM isopropyl-β-thiogalactopyranoside and allowed 
to grow overnight.  The cells were then harvested by centrifugation at 4oC, 8000 x g for 20 min.  
Cell pellets were obtained and dissolved in a lysis buffer (20 mM Tris pH 8.5, 300 mM NaCl, 
5% glycerol) and the re-suspended mixture was disrupted using a cell disruptor.  The cell debris 
was centrifuged at 4oC and 27000 x g for 1 hour.  The supernant was obtained and subjected to 
an affinity column (Ni-NTA resin, 26 x 200 mm) and eluted at a flow rate of 4 mL/min by using 
a linear imidazole gradient generated from buffer A (20 mM Tris-base, pH 8.0, 300 mM  NaCl, 
5mM imidazole, 5% glycerol) and 0-80% of buffer B (20 mM Tris-base, pH 8.0, 300 mM NaCl, 
500 mM imidazole, 5 % glycerol).  The hADO fraction was then concentrated and loaded onto a 
size exclusion column HiLoad Superdex 200 and eluted at a flow rate of 2 mL/min with a 
desalting buffer (10 mM Tris-base, pH 8.0, 5% glycerol). 12% SDS-PAGE was used to monitor 
and confirm that the peak had a consisted weight to that of the theoretical molecular weight of 
hADO mono (MW= 29 KDa).   
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Figure 6. Plasmid map of ADO. 
 
 
Figure 7. FPLC elution profile from Ni-NTA column and Superdex 75 on hADO. 
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Figure 8. SDS-PAGE of hADO w/o DTT and with DTT after Superdex 75. 
 
 
Figure 9. SDS-PAGE of hADO before and after treatment with 3mM substrate. A and B 
corresponds to hADO before treatment with substrate and A1 and B1 is after treatment with 
substrate.  
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2.2 hADO Crystallization Parameters 
Crystals were observed for hADO protein prepared by two different methods.   
2.2.1 As Isolated hADO without His-tag 
hADO purified from HiLoad Superdex 75 was incubated with TEV protease (1:10 ratio) 
with stirring overnight at 4oC.  The TEV treated hADO was then subjected to a 5 mL Ni-NTA 
resin and eluted at a flow rate of 1.5 mL with a linear imidazole gradient generated from buffer 
A and buffer B. The hADO fraction was concentrated and loaded onto a desalting column and 
eluted with the desalting buffer without any glycerol.  
2.2.2 hADO without His-tag reconstituted with Fe 
hADO without His6-tag were incubated with 20mM EDTA while stirring overnight at 
4oC.  The EDTA-treated hADO was then loaded onto a desalting column and eluted with the 
desalting buffer to remove any EDTA.  The collected EDTA treated protein was then made 
anaerobic via a shrink line under constant N2 gas.  In an anaerobic glove box, iron ammonium 
sulfate was dissolved in anaerobic water and added to the anaerobically prepared hADO.  The 
Fe-reconstituted hADO was then subjected to another desalting via a desalting column with 
desalting buffer without glycerol.   
2.3 Screening by Hampton Crystal Kits 
hADO prepared as previously mentioned were screened by approximately 100 different 
conditions each experiment using Hampton research crystal screen kits at varying protein 
concentrations (10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL, 30 mg/mL).  Fresh DTT or 
cysteamine substrate was prepared and 1mM or 10 mM of substrate were added to each protein 
concentration prior to screening.  1 uL of each protein concentration was mixed with 1 uL of 
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mother liquor via a Crystal Screen Robot via micro-batch diffusion method and stored and 
monitored at 16°C until crystals were observed and harvested.  
The hADO crystals were harvested from the drops and flash frozen with liquid nitrogen 
and sent to SER-CAT for remote analysis.  The diffraction data were collected at SER-CAT 
beam ID-22 or BM-22 line with 180 frames.    
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3     RESULTS 
Evidence of potential crystals was observed at multiple conditions.  Screening with Fe-
reconstituted hADO yielded in unstable and un-harvestable seed shaped crystals at various 
conditions.  The crystals from Figure 8  were the result of 15mg/mL hADO protein, 0.2M 
ammonium acetate, 0.1M Hepes pH 7.5, 45%v/v-2-methyl-2,4, pentanediol where 1 mM 
substrate was added to hADO resulting in A and 10 mM substrate for the crystal formed in 
B.  
 
 
Figure 10. Seed-like hADO crystals were observed from the same condition at two 
different substrate concentration. 
 
Crystals from C in Figure 9 resulted from 20 mg/mL of hADO, 10 mM substrate, 0.2M 
potassium tartrate tetrahydrate, 0.1M sodium citrate tribasic dehydrate pH 5.6, 2.0 M 
ammonium sulfate.  Crystal D was the result of 15 mg/mL hADO protein, 10mM substrate, 
0.2M lithium sulfate monohydrate, 0.1M Bis-Tris pH 5.5, and 25% w/v PEG 3350.  
 
A B 
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Figure 11. Seed-like hADO crystals observed with Fe-reconstituted hADO.  
               
A different hADO crystal structure was observed at 15 mg/mL (E) and 20 mg/mL hADO 
(F), 0.2 Sodium fluoride, 20% w/v PEG 3350 from Fe-reconstituted hADO shown on Figure 
10. The crystals were collected stable and robust enough to be collected. 
 
Figure 12. Flower-like hADO crystals observed with Fe-reconstituted hado. 
   
C D 
E F 
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hADO crystals without Fe reconstitution yielded in a long rod crystal rod at the condition of 
20 mg/mL hADO, 0.1 M Sodium cacoldylate trihydrate pH 6.5, 0.1 M Sodium acetate 
trihydrate  (Figure 11).   
 
 
Figure 13. Rod-shaped hADO crystals 
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Figure 14. SER-CAT beam analysis of hADO crystals from Figure 9. 
 
 
 
 
Figure 15. SER-CAT beam analysis of hADO crystals from Figure 9. 
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Figure 16. SER-CAT imaging analysis of the rod-shaped hADO. 
 
4 DISCUSSION 
ADO is non-heme mononuclear iron dependent enzyme that catalyzes the oxidation of 
cysteamine to hypotaruine in the presence of oxygen.  To date, no structure of ADO has 
been reported.  Blasts study indicates that CDO is the closest relative of ADO but only with 
approximately 19% sequence similarity.  Findings from the structure of CDO indicate that 
CDO utilizes a 3-His metal binding motif.  Sequence study also indicates that ADO also has 
this conserved 3-His metal binding motif.  The structure of an enzyme is a crucial factor for 
indebt mechanistic study and understanding the regulation roles of the enzyme in vivo.   
Recombinant hADO cloned to pET28 plasmid with a His-tag was successfully 
cloned and purified as previously mentioned above.  The purification conditions allowed for 
optimal purification of the protein normally yielding on average of 1-3 mg/mL. Ni-NTA 
purification of hADO showed an elution profile with normally one distinctive peak (Figure 
5).  SDS-PAGE of the protein after Ni-NTA shows two distinctive major bands 
approximately at 29 KDa and 58 KDa.  Further purification of hADO with Superdex 75 will 
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result in typically 3 peaks (Figure 5). Peak 1does not show absorbance at 280 nm and does 
not show any bands when analyzed by SDS-PAGE, thus indicating that it is not the desired 
protein hADO.  It does absorb strongly at 260 nm, suggesting that it could be from DNA.  
Peak 2 and peak 3 both show strong protein absorbance at 280nm and SDS-PAGE further 
validated the expected two bands of hADO (Figure 6). The protein proved to be rather 
stable, making it optimal to handle the protein without constant freezing of protein as long 
as the protein was kept under ice.  
Crystallization screenings of hADO yielded in various potential conditions from the 
tested parameters.  Initial screenings of hADO with His-tag intact resulted in lack of protein 
crystal formation.  His-tag removal via TEV protease helped increase potential crystal 
formation for the protein.  It has previously been reported for CDO and other proteins that 
His-tag removal may help in stabilizing the protein.  The flexible tail end from His-tag may 
disrupt proper protein nucleation. However, this is not true for all scenarios as it has been 
shown that some proteins are easier and able to be crystallize with the his-tagg still intact. 
When removed and purified from bacterial cell, hADO tends to for a mixture of monomer 
and dimer as indicated from SDS-PAGE.   When DTT is added to the loading buffer gel, the 
normally seen two bands converge into just one single band (Figure 6).  This suggests that 
the ADO eluted from the size exclusion column are in different multimer forms.  This 
resulted in initially screenings with DTT as a reducing agent for hADO at various 
concentrations in order to keep hADO in a monomeric form.  Crystal formation was 
observed after these modifications, however the crystals observed did not have a definitive 
shape and were highly unstable during crystal harvest. One key finding was that the 
substrate cysteamine was able to reduce hADO to a monomer in the same manner that DTT 
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can as indicated via SDS-PAGE (Figure 7).  It has been shown previously that substrate can 
help to stabilize and support protein during crystallization11,13. This finding facilitated the 
usage of the substrate cysteamine as a substitute for DTT as a reducing agent.  
CDO has been previously reported to incorporate various divalent metals as a cofactor as 
Mccoy and Stipanuk’s was able to crystallize CDO with nickel and iron respectively.   
Based on this notion, crystallization of hADO was explored with different metals.  No 
results were obtained from crystallization of hADO with nickel however, hADO with Fe-
reconstituted did result in formation of low diffracting crystals.  Even though Fe has been 
noted to be the preferred metal for catalysis, it has been proven by various groups that the 
native metal is not always the desired metal needed for crystallization conditions. Test 
revolving around as purified hADO without metal reconstitution or EDTA treatment yielded 
in a crystal structure of a rod, very different from hADO reconstituted with Fe. hADO 
grown in Luria broth will be incorporated with various metals ranging due to trace amounts 
of metals present in the Luria broth.  Thus, the identity of the metal resulting in the 
formation of the rod crystal is unknown. The rod crystal collected also resulted in slightly 
diffracting crystals but proved to be promising as it has been noted by Stipanuk that 
crystallization of hCDO also resulted in rod-shaped crystals. 
 
1 CONCLUSION 
These results have helped to reveal crucial conditions needed for the structure elucidation 
of hADO.  From the nature of the crystal formation and diffraction patterns of the analyzed 
crystals, it is evident that the crystals obtained are not from salt formation. The results for 
hADO prove to be promising with various parameters needing to be refined in order to solve 
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the structure.  For future work, the range of protein concentration of hADO should be 
explored in higher concentrations as the protein has shown promise to crystallize in 
concentration ranges from 15-25 mg/mL.  More emphasis could also be focused on the 
metal cofactor which seems to play a role in the types of hADO crystals formed.  Apo 
protein along with other divalent metals other than Fe can be explored as crystallization 
parameters.  The role of the substrate cysteamine as a natural reducing agent has proven to 
be a crucial factor for crystal stability for harvesting; however various other reducing agents 
such as previously tested DTT should be revisited and tested at various concentrations.  
Once the optimal conditions for hADO crystals are determined, then procedures for phasing 
for a de novo structure needs to be implemented.  This could be through various methods 
such as heavy metal soaking by incubating the protein crystals with metals such as Pt, Au, 
etc for a short time. Another approach is growing the protein with M9 media that is 
substituted with Set-Met. 
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